Marinus Pharmaceuticals

Immedica Pharma US Inc.

Alex Aimetti

Joseph Hulihan

Scott Braunstein

Lorianne Masuoka

David Czekai

Maciej Gasior

Julia Tsai

Christopher Cashman

Jaakko Lappalainen

The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.

Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders

This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides SE suppression and continued suppression of SE.

Ganaxolone for use in treatment of status epilepticus

The disclosure to methods for treating tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable pregnenolone neurosteroid, such as ganaxolone, to reduce one or more symptoms of tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy.

Ganaxolone for use in treating tuberous sclerosis complex

Uses of ganaxolone in prophylaxis and treatment of postpartum depression are described. A dose of ganaxolone is administered to a female suffering from postpartum depression or at risk of developing postpartum depression in an amount and at a rate sufficient to alleviate at least one symptom of postpartum depression in the female.

Growing community of inventors

Radnor, PA, United States of America

Alex Aimetti